Condition
SGLT 2 Inhibitors
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Recruiting1
Active Not Recruiting1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07292909Phase 4Recruiting
Effect of Empagliflozin on Inflammation
NCT07204743Not ApplicableActive Not RecruitingPrimary
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
NCT07186153Not Yet RecruitingPrimary
Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling in Diabetic Patients
NCT05857085Phase 4Completed
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
Showing all 4 trials